Second, individuals who have previously received limited BRCA1 and BRCA2 gene testing may still harbor a genetic risk of breast and/or ovarian cancer and should be considered for multi-gene panel testing including large rearrangement testing. The gene discussed is BRCA1; the disease is ovarian carcinoma.